2015 BPD Header

Cambridge Healthtech Institute’s 2nd Annual
Cell Therapy Bioproduction
Industrializing Cell Therapies
August 3-4, 2015
Part of CHI's 7th Annual The Bioprocessing Summit

August 3-7, 2015 | Westin Copley Place Hotel | Boston, Massachusetts


Continuing the discussions initiated at last year’s Cell Therapy Bioproduction conference and building upon the industry’s increasing knowledge and experience in this field, we have identified the top challenges that scientists and engineers are struggling with, which range from translation from bench to clinic, to commercial scaling up from 2D to 3D cultures, product characterization and analytics, QC and process validation, as well as commercialization hurdles such as COGS and procurement.

CHI’s Second Annual Cell Therapy Bioproduction aims to open the communication channels between pharma, academia and vendors by presenting first-hand case studies, practical examples, proven concepts and novel technologies to help provide potential solutions to these challenges.


Preliminary Agenda 


KEYNOTE PRESENTATION

I’m From the Government and I’m Here to Help - Navigating the Global Regulatory Maze for Cellular Therapeutics

Anthony Davies, Ph.D., President, Dark Horse Consulting, Inc.


SOURCING AND PROCREMENT OF RAW MATERIALS

Qualification of Raw Materials for Cell Therapy

Fouad Atouf, Ph.D., Director, Biologics and Biotechnology, U.S. Pharmacopeia

Sourcing and Qualification of Starting Cellular Materials

Elizabeth Read, Consultant, EJ Read Consulting LLC


BIOREACTOR DESIGN AND CELL CULTURE AND EXPANSION STRATEGIES

Perfused Bioreactor for the Optimization of Human Stem Cell Culture

Veronique Chotteau, Ph.D., Principal Investigator, Cell Technology Group, School of Biotechnology, KTH, Royal Institute of Technology

Cell Expansion and Scaling Up in 3D: Implementing an Optimized, Standardized and Fully Automated Operation

Ohad Karnieli, Ph.D., VP Technology and Manufacturing, Pluristem Therapeutics


SCALE-UP AND MANUFACTURING

Optimization and Clinical Manufacturing of Chimeric Antigen Receptor (CAR) T Cells for Solid Tumors

Pranay D. Khare, Ph.D., Director, Cancer Immunotherapy and Gene Therapy cGMP Facility, Roger Williams Medical Center

Overcoming Comparability and Scale-Up Challenges in Cell Therapy Production

Robert Deans, Ph.D., Executive VP, Regenerative Medicine, Athersys, Inc.

Commercialization of an Autologous Cell Therapy Product (tentative title)

Knut Niss, Ph.D., Sr Technical Project Leader, Novartis Pharmaceuticals Corp.




For more details on the conference,
please contact:

Mimi Langley
Sr. Conference Director
Phone: (+1) 816-471-0701
Email: mlangley@healthtech.com 

For exhibit & sponsorship opportunities, please contact: 

Companies A-K:
Elizabeth Lemelin
Business Development Manager
Phone: 781-972-1342
Email: elemelin@healthtech.com 

Companies L-Z:
Sherry Johnson
Business Development Manager
Phone: 781-972-1359
Email: sjohnson@healthtech.com